Authors
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Rebecca Epperly, MD, on Research Considerations as CAR-T Therapy Comes of AgeThe clinical investigator in the Department of Bone Marrow Transplantation & Cellular Therapy at St. Jude Children’s Research Hospital discussed several areas of interest for research now that CAR-T is here to stay.
Latest:
Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhDThe hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
Latest:
Alexis Kuhn, PharmD, BCOP, on Hemoglobinopathy Gene Therapies From a Pharmacist’s PerspectiveThe pediatric oncology pharmacist at Mayo Clinic discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
Latest:
Laurent Poirot, PhD, on the FDA’s IND Clearance for UCART20x22The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.
Latest:
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg CellsThe senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.
Latest:
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal CancerFang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
Improving Rare Disease Awareness: Bruce Dezube, MDThe senior vice president and head of clinical development at Mustang Bio discussed the importance of Rare Disease Day.
Latest:
CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MDThe hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Latest:
George Tachas, PhD, on Tackling DMD Treatment From Multiple AnglesThe lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.
Latest:
Tim Miller, PhD, on Supporting Gene Therapy DevelopmentThe cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
Latest:
The Future of Gene Therapies in Inherited Retinal DiseasesMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Latest:
Advantages of Invariant Natural Killer T Cell TherapiesJennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed the company’s iNKT cell platform.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
John Leonard, PhD, on RNA-Targeting Gene Therapy for ALS, DMDThe chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.
Latest:
Fostering Collaboration in Cell and Gene Therapy ResearchNathan Yozwiak, PhD, the head of research at the Gene and Cell Therapy Institute at Mass General Brigham, discussed the Institute’s efforts to bring about clinical translation of preclinical work.
Latest:
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene TherapyThe codirector of the MDA Clinic and professor of neurology at Johns Hopkins discussed the importance of continuing to fight for progress with older patients with SMA.
Latest:
David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMDThe senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
Latest:
Electrotransfection: A Different Approach to Plasmid DeliveryThe chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.
Latest:
Daniel Judge, MD, on Translational Gene Therapy for Cardiac DisordersGenetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.
Latest:
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple MyelomaThe senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Latest:
Paula Cannon, PhD, on What Attendees Can Look Forward to at ASGCT’s 2024 MeetingThe President Elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC also discussed recent milestones in gene therapy.
Latest:
Ula V. Jurkunas, MD: CALEC Transplant Feasible for Limbal Stem Cell DeficiencyThe associate professor of ophthalmology at Harvard Medical School discussed early results from a phase 1/2 trial from Mass Eye and Ear and partners.
Latest:
Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy ArsenalThe cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Latest:
Bone Marrow DNA Sequencing Predicts Acute Lymphoblastic Leukemia Relapse After TisagenlecleucelFindings from the phase 2 ENSIGN and ELIANA studies suggest DNA sequencing predicts ALL relapse.
Latest:
Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor RelapseSimeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.
Latest:
Francesca Del Bufalo, MD, PhD, on Evaluating GD2-Directed CAR-T in Pediatric NeuroblastomaThe medical doctor and scientist at Bambino Gesù Chidren’s Hospital discussed phase 1/2 clinical trial data she presented at ASGCT’s 2024 Meeting.
Latest:
Florian Eichler, MD, on Addressing Unmet Needs in Canavan Disease With Gene TherapyThe neurologist at Massachusetts General Hospital discussed BBP-812, an investigational AAV vector-based gene therapy being evaluated for Canavan disease in a phase 1/2 trial.
